about
Drug biotransformation: mechanistic studies with stable isotopesThe metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites.Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids.Idiosyncratic reactions: new methods of identifying high-risk patients.Influence of small doses of various drug vehicles on acetaminophen-induced liver injury.Hepatoprotective role of liver fatty acid binding protein in acetaminophen induced toxicity.Acute Toxicity-Supported Chronic Toxicity Prediction: A k-Nearest Neighbor Coupled Read-Across Strategy.Immunohistochemical localization and quantification of the 3-(cystein-S-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity.The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions.Metabolism of xilobam in laboratory animals and man.A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity.Practical approaches to resolving reactive metabolite liabilities in early discovery.Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity.Enzymatic activation of chemicals to toxic metabolites.Chemically induced renal papillary necrosis and upper urothelial carcinoma. Part 1.Chemically induced renal papillary necrosis and upper urothelial carcinoma. Part 2.Domestication of chemistry by design of safer chemicals: structure-activity relationships.Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury.Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man.Changes in the antioxidant system in epileptic children receiving antiepileptic drugs: two-year prospective studies.The role of cytochrome-P450 inhibitors in the prevention of hepatotoxicity after paracetamol overdose in rats.Assessment of the genotoxic and carcinogenic potentials of 3-aminothiophene derivatives using in vitro and in silico methodologies.Ameliorative effect of naringin in acetaminophen-induced hepatic and renal toxicity in laboratory rats: role of FXR and KIM-1.Identification of phenacetin metabolites in human urine after administration of phenacetin-C2H3: Measurement of futile metabolic deacetylation via HPLC/MS-SPE-NMR and HPLC-ToF MS
P2860
Q28303814-ED9E2631-0C16-4CAA-A382-1A901C16A14BQ28361778-3671F808-06B4-46F8-834E-930870F0B2BEQ30304066-AD3242F6-1DAC-4A56-B8E8-7A577C3399D4Q34090578-6BE3C0FB-49D0-4BF4-B0A9-C1936E5AFB69Q34144857-E13C77B3-184E-4AD6-8706-AED59E60771EQ35114156-F181EB1A-36E4-4697-B7D1-5E7CDF4F977AQ35640623-7244BE28-840A-41C3-94F2-1EE9F144ACDEQ35830716-724F0C9A-DE5E-458C-A6C2-D85A938DA504Q36312078-F49AA353-39AE-4111-8D74-756D6E60B66DQ36728417-0C6C4B9F-C58D-40BA-82D1-2B2CFAB983B1Q37950014-613824F9-378E-41AC-9972-A55A3BF3A785Q38269781-B0B78A70-ACD0-40F6-B300-F01A87B75ACFQ38297772-ABB7D171-52E4-4D91-AF83-43C5F519E0B8Q39847955-921625D1-4620-4792-88B0-42339A8008AEQ39849913-4A08ACDA-72A1-46DE-8554-3D9202A32CADQ39850291-7AD9BC27-B15A-4D8A-83E1-4DA49828DA52Q40189612-1AF75B8F-140A-441C-BFA0-0B6C7BD2A4D0Q40817414-8D1FD63C-7634-4AB9-A959-71C77DD33493Q43692530-C33D7A73-B064-45B8-9CAF-3E8548A46113Q43711273-17FE610B-6FC0-4322-A07B-11F777EB775EQ44803422-B5AD1B87-BDB6-4AC6-8FB1-5DDB54C4BD80Q50007810-5E540DC6-B478-420F-A371-8DFE0E7C6CC8Q52876599-51C822D0-2117-4C71-8551-8D5DBE54F169Q58045908-D38F04D0-B39F-44C6-B959-FB079EE2809D
P2860
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
Metabolic activation and drug toxicity.
@en
type
label
Metabolic activation and drug toxicity.
@en
prefLabel
Metabolic activation and drug toxicity.
@en
P356
P1476
Metabolic activation and drug toxicity.
@en
P2093
P304
P356
10.1021/JM00349A001
P407
P577
1982-07-01T00:00:00Z